MedTrace Logo

Post-Operative Nausea And Vomiting Study In Female Patients

NCT00274690 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 435

Last updated 2017-01-20

No results posted yet for this study

Summary

The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.

Conditions

  • Postoperative Nausea and Vomiting
  • Nausea and Vomiting, Postoperative

Interventions

DRUG

GW679769

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2005-08-31
Completion
2005-08-31

Countries

  • United States
  • Denmark
  • Hong Kong
  • Hungary
  • Israel
  • Norway
  • Philippines
  • Slovenia
  • Spain
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00274690 on ClinicalTrials.gov